

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature _____

Date _____

| | | |
|---|---------------------------|--------------------------|
| First Applicant: | Bueno Melendo, Ana Belen | Group Art Unit: 1624 |
| Serial No.: | 10/599,125 | Examiner: B. McDowell |
| Application Date: | April 8, 2005 | Confirmation No.: 4566 |
| US Nat'l Entry Date (if applicable): | September 20, 2006 | |
| For: | AMIDES AS BACE INHIBITORS | |
| Docket No.: | X-16772 | |

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicants have previously submitted an Information Disclosure Statement (IDS) and Form PTO-1449 for consideration by the Examiner on September 20, 2006. Now, pursuant to 37 C.F.R. 1.97(c), Applicants submit this Supplemental IDS and attached amended Form PTO-1449 to bring to Examiner's attention the claims from US 2007-0213331 for which a notice of allowance was received on June 3, 2009. These newly allowed claims are the US cognate of WO 2005/108358 which was previously presented to the Examiner in the IDS filed on September 20, 2006.

Since this statement is being filed after the period specified in 37 C.F.R. 1.97(b) but before the mailing date of a final action or a notice of allowance, please charge the fee under 37 C.F.R. 1.17(p) to Deposit Account No. 05-0840 in the name of Eli Lilly and Company.

Respectfully submitted,

/Elizabeth A. Dingess-Hammond/


Elizabeth A. Dingess-Hammond
Agent for Applicants
Registration No. 63,996
Phone: 317-433-3689

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

August 14, 2009_____

We Claim:

2. A compound of Formula I(a):



I(a)

where:

R^1 is $(C_3-C_7 \text{ cycloalkyl})_{0-1}(C_1-C_6 \text{ alkyl})$;

R^2 is benzyl optionally mono- or difluorinated in the phenyl ring;

R^6 is R^{34} , $-\text{CH}_2\text{C}(\text{O})\text{R}^{35}$;

R^{32} is C_1-C_{10} alkyl optionally substituted with 1-6 fluorine atoms, oxo, or one or two hydroxy groups, C_2-C_6 alkenyl, or $-(\text{CH}_2)_{0-3}\text{R}^{33}$;

R^{33} is C_3-C_7 cycloalkyl or phenyl each optionally substituted with one or two substituents independently selected from the group consisting of halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, trifluoromethyl, and trifluoromethoxy, or R^{33} is adamantyl;

R^{34} is $-(\text{CH}_2)_{0-2}\text{OR}^{32}$;

R^{35} is hydroxy, C_1-C_6 alkoxy, or $\text{NR}^{37}\text{R}^{38}$ where R^{37} and R^{38} are independently hydrogen or C_1-C_6 alkyl, or R^{37} and R^{38} , taken together with the nitrogen to which they are attached, form a piperidine ring optionally substituted with C_1-C_6 alkyl, a homopiperidine ring, a morpholine ring, or a pyrrolidine ring optionally substituted with $(C_1-C_6 \text{ alkoxy})\text{methyl}$;

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of Claim 2, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

13. A compound of Claim 2 where R^2 is benzyl.